Literature DB >> 9740698

Radiation therapy of pelvic recurrence after radical hysterectomy for cervical carcinoma.

T Ijaz1, P J Eifel, T Burke, M J Oswald.   

Abstract

OBJECTIVES: To evaluate the efficacy of radiation therapy and potential prognostic factors in patients treated for pelvic recurrence of cervical carcinoma after radical hysterectomy. MATERIALS: The records of 50 patients treated between 1964 and 1994 for an isolated pelvic recurrence of cervical carcinoma a median of 10.5 months after initial radical hysterectomy were retrospectively reviewed. Patients were categorized according to the extent of disease on clinical examination as group 1, mucosal involvement only (5); group 2, paravaginal extension (11); group 3, central recurrence with pelvic wall extension (13); and group 4, recurrences limited to the pelvic sidewall (21). Seven patients with group 3 or 4 disease who had a poor performance status were treated with palliative intent using hypofractionated radiotherapy. The remaining 43 patients were treated with curative intent, 33 with radiotherapy only and 10 with a combination of cisplatin-based chemotherapy and radiotherapy. Survival rates were calculated from the date of initial recurrence. Median follow-up of surviving patients was 109 months.
RESULTS: The overall 5-year survival rate was 33% for all 50 patients (median survival, 18 months), 39% for the 43 patients treated with curative intent, and 25% for patients with isolated sidewall recurrences treated with curative intent. The survival rate was 69% for patients with group 1 and 2 disease and 18% for those treated with curative intent for group 3 disease (P = 0.07). The survival rate was better for patients with recurrent squamous carcinomas (51%) than for those with adenocarcinomas (14%) (P = 0. 05). Three group 4 patients who survived more than 5 years were treated with external-beam radiation alone. Eight-one percent of patients who had a second recurrence had evidence of disease progression. Three patients experienced late treatment complications.
CONCLUSIONS: Patients who experience an isolated recurrence of cervical cancer after initial radical hysterectomy have an excellent prognosis if disease does not involve the pelvic wall. Occasional long-term survivors of recurrent disease involving the pelvic wall justify an aggressive treatment approach. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9740698     DOI: 10.1006/gyno.1998.5093

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  13 in total

1.  Salvage radiotherapy with or without concurrent chemotherapy for pelvic recurrence after hysterectomy alone for early-stage uterine cervical cancer.

Authors:  Sang-Won Kim; Mison Chun; Hee-Sug Ryu; Suk-Joon Chang; Tae Wook Kong; Eun Ju Lee; Yong Hee Lee; Young-Taek Oh
Journal:  Strahlenther Onkol       Date:  2017-03-29       Impact factor: 3.621

2.  Treatment options in recurrent cervical cancer (Review).

Authors:  Angiolo Gadducci; Roberta Tana; Stefania Cosio; Luca Cionini
Journal:  Oncol Lett       Date:  2010-01-01       Impact factor: 2.967

3.  Recurrent uterine cancer after surgery: magnetic resonance imaging patterns and their changes after concomitant chemoradiation.

Authors:  R Manfredi; S Baltieri; A Tognolini; R Graziani; D Smaniotto; N Cellini; L Bonomo
Journal:  Radiol Med       Date:  2008-09-08       Impact factor: 3.469

Review 4.  What is the evidence for the clinical value of SBRT in cancer of the cervix?

Authors:  Loreto Yanez; Ana M Ciudad; Minesh P Mehta; Hugo Marsiglia
Journal:  Rep Pract Oncol Radiother       Date:  2018-10-09

5.  Microvessel density and p53 in detecting cervical cancer by FDG PET in cases of suspected recurrence.

Authors:  Astrid A M van der Veldt; Lotty Hooft; Paul J van Diest; Johannes Berkhof; Marrije R Buist; Emile F I Comans; Otto S Hoekstra; Carla F M Molthoff
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07-14       Impact factor: 10.057

6.  Survival and Control Prognosticators of Recurrent Gynecological Malignancies of the Pelvis and Para-aortic Region Treated with Stereotactic Body Radiation Therapy.

Authors:  Shaakir Hasan; Anthony Ricco; Kaylette Jenkins; Rachelle Lanciano; Alexandra Hanlon; John Lamond; Jun Yang; Jing Feng; Michael Good; Joel Noumoff; Luther Brady
Journal:  Front Oncol       Date:  2016-11-22       Impact factor: 6.244

7.  High-dose-rate intracavitary brachytherapy for recurrent cervical cancer in the vaginal stump after hysterectomy.

Authors:  Yuka Kozai; Yoshiyuki Itoh; Mariko Kawamura; Rie Nakahara; Junji Ito; Tohru Okada; Fumitaka Kikkawa; Mitsuru Ikeda; Shinji Naganawa
Journal:  Nagoya J Med Sci       Date:  2019-08       Impact factor: 1.131

8.  High-dose-rate interstitial brachytherapy with hypoxic radiosensitizer KORTUC II for unresectable pelvic sidewall recurrence of uterine cervical cancer: a case report.

Authors:  Mio Nakata; Ken Yoshida; Taiju Shimbo; Nobuhiko Yoshikawa; Hiroto Yoshioka; Akihiro Hori; Chikara Sato; Yasuo Uesugi; Yuhei Kogata; Koji Masui; Naoya Murakami; Tairo Kashihara; Hironori Akiyama; Nikolaos Tselis; Masahide Ohmichi; Keiji Nihei
Journal:  J Contemp Brachytherapy       Date:  2020-12-16

9.  Intraoperative Electron Beam Radiotherapy (IOERT) in the management of locally advanced or recurrent cervical cancer.

Authors:  Brandon M Barney; Ivy A Petersen; Sean C Dowdy; Jamie N Bakkum-Gamez; Kristi A Klein; Michael G Haddock
Journal:  Radiat Oncol       Date:  2013-04-08       Impact factor: 3.481

10.  Role of F-18 fluorodeoxyglucose positron emission tomography/computed tomography in the detection of recurrence in patients with cervical cancer.

Authors:  Amit Bhoil; Bhagwant Rai Mittal; Anish Bhattacharya; Sampath Santhosh; Firuza Patel
Journal:  Indian J Nucl Med       Date:  2013-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.